Global Lipid Contract Manufacturing Market Growth (Status and Outlook) 2023-2029

Global Lipid Contract Manufacturing Market Growth (Status and Outlook) 2023-2029

Liposomes and lipid nanoparticles (LNPs) are similar by design, but slightly different in composition and function. Both are lipid nanoformulations and excellent drug delivery vehicles, transporting cargo of interest within a protective, outer layer of lipids. In application, however, LNPs can take a variety of forms.Innovators in the biopharmaceutical industry have developed a number of ways to improve/augment physiochemical properties and ultimately, the drug-like behavior of pharmacological substances. Amidst other alternatives, lipid nanoparticles and liposomes are the main type.Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.Liposomes and Lipid Nanoparticles are delivery carriers, the primary lipids used to make liposomes or Lipid Nanoparticles are Phospholipids, Pegylated Lipids, Ionizable Lipids (Cationic / Anionic Lipids), Triglycerides, Sphingolipids, Neutral Lipids, etc. In our report, we mainly study the Liposomes and Lipid Nanoparticles (LNP) Contract Manufacturing as delivery carriers.
LPI (LP Information)' newest research report, the “Lipid Contract Manufacturing Industry Forecast” looks at past sales and reviews total world Lipid Contract Manufacturing sales in 2022, providing a comprehensive analysis by region and market sector of projected Lipid Contract Manufacturing sales for 2023 through 2029. With Lipid Contract Manufacturing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lipid Contract Manufacturing industry.
This Insight Report provides a comprehensive analysis of the global Lipid Contract Manufacturing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lipid Contract Manufacturing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lipid Contract Manufacturing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lipid Contract Manufacturing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lipid Contract Manufacturing.
The global Lipid Contract Manufacturing market size is projected to grow from US$ 998.4 million in 2022 to US$ 928.8 million in 2029; it is expected to grow at a CAGR of -1.0% from 2023 to 2029.
Global core lipid contract manufacturing companies include Merck KGaA, Exelead and Avanti Polar Lipids etc. The top 3 companies hold a share about 38%. North America is the largest market, with a share over 60%, followed by Europe and APAC with the share about 26% and 12%.
In terms of product, lipid nanoparticles is the largest segment with a share about 79%. And in terms of application, the largest application is commercial with a share about 67%, followed by clinical and preclinical.
This report presents a comprehensive overview, market shares, and growth opportunities of Lipid Contract Manufacturing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Liposomes
Lipid Nanoparticles
Segmentation by application
Preclinical
Clinical
Commercial
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.